Measles surveillance in Canada: 2018.

measles measles elimination surveillance travel health vaccination

Journal

Canada communicable disease report = Releve des maladies transmissibles au Canada
ISSN: 1188-4169
Titre abrégé: Can Commun Dis Rep
Pays: Canada
ID NLM: 9303729

Informations de publication

Date de publication:
02 Apr 2020
Historique:
entrez: 20 6 2020
pubmed: 20 6 2020
medline: 20 6 2020
Statut: epublish

Résumé

Measles has been eliminated in Canada since 1998. Every year, the Public Health Agency of Canada presents epidemiologic evidence to the Pan American Health Organization (PAHO) to verify that measles continues to be eliminated in Canada. The objectives of this article are to: provide an epidemiologic summary of measles activity reported in 2018 in Canada, and provide documented evidence to support the continued verification of measles elimination status in Canada. Measles surveillance data were captured by the Canadian Measles and Rubella Surveillance System (CMRSS) and descriptive analyses of demographics and risk factors were performed. Outbreak characteristics were summarized and genotypic analyses conducted. Surveillance data for 2018 were evaluated against PAHO's essential criteria for measles elimination status. In 2018, 29 measles cases were reported across five provinces in Canada, an incidence rate of 0.8 cases per 1,000,000 population. Of these 29 cases, 16 were imported and five resulted in further transmission within Canada. The age-specific incidence rate was highest among those aged younger than one year (10.2 cases per 1,000,000 population, n=4). Only nine cases were considered up-to-date for measles vaccination, and 11 cases were hospitalized. Genotype information was available for most of the measles cases (n=27); they were all found to be genotypes that circulated globally in 2018. Canada met or partially met three out of four of PAHO's criteria for verification of measles elimination. Although importations and areas of low vaccination coverage continue to challenge Canada's elimination status, there is no evidence that endemic transmission of the measles virus has been re-established. Canada maintains its measles elimination status.

Sections du résumé

BACKGROUND BACKGROUND
Measles has been eliminated in Canada since 1998. Every year, the Public Health Agency of Canada presents epidemiologic evidence to the Pan American Health Organization (PAHO) to verify that measles continues to be eliminated in Canada. The objectives of this article are to: provide an epidemiologic summary of measles activity reported in 2018 in Canada, and provide documented evidence to support the continued verification of measles elimination status in Canada.
METHODS METHODS
Measles surveillance data were captured by the Canadian Measles and Rubella Surveillance System (CMRSS) and descriptive analyses of demographics and risk factors were performed. Outbreak characteristics were summarized and genotypic analyses conducted. Surveillance data for 2018 were evaluated against PAHO's essential criteria for measles elimination status.
RESULTS RESULTS
In 2018, 29 measles cases were reported across five provinces in Canada, an incidence rate of 0.8 cases per 1,000,000 population. Of these 29 cases, 16 were imported and five resulted in further transmission within Canada. The age-specific incidence rate was highest among those aged younger than one year (10.2 cases per 1,000,000 population, n=4). Only nine cases were considered up-to-date for measles vaccination, and 11 cases were hospitalized. Genotype information was available for most of the measles cases (n=27); they were all found to be genotypes that circulated globally in 2018. Canada met or partially met three out of four of PAHO's criteria for verification of measles elimination.
CONCLUSION CONCLUSIONS
Although importations and areas of low vaccination coverage continue to challenge Canada's elimination status, there is no evidence that endemic transmission of the measles virus has been re-established. Canada maintains its measles elimination status.

Identifiants

pubmed: 32558823
doi: 10.14745/ccdr.v46i04a04
pii: 460404
pmc: PMC7279125
doi:

Types de publication

Journal Article

Langues

eng

Pagination

77-83

Déclaration de conflit d'intérêts

Conflict of interest: None.

Références

Ann Epidemiol. 1992 Nov;2(6):805-12
pubmed: 1342333
J Infect Dis. 2011 Sep 1;204 Suppl 2:S683-9
pubmed: 21954267
Can Commun Dis Rep. 2013 Oct 30;39(ACS-3):1-52
pubmed: 31696866
MMWR Morb Mortal Wkly Rep. 2019 Dec 06;68(48):1105-1111
pubmed: 31805033
Wkly Epidemiol Rec. 2015 Jul 24;90(30):373-80
pubmed: 26211016
MMWR Morb Mortal Wkly Rep. 2018 Nov 30;67(47):1323-1329
pubmed: 30496160
J Infect Dis. 2011 Jul;204 Suppl 1:S514-23
pubmed: 21666208
MMWR Morb Mortal Wkly Rep. 2015 Oct 02;64(38):1088-92
pubmed: 26421903
J Infect Dis. 2004 May 1;189 Suppl 1:S236-42
pubmed: 15106117
Wkly Epidemiol Rec. 1998 Aug 28;73(35):265-9
pubmed: 9745371

Auteurs

Cameron Coulby (C)

Centre for Immunization and Respiratory Infectious Diseases, Public Health Agency of Canada, Ottawa, ON.

Francesca Reyes Domingo (FR)

Centre for Immunization and Respiratory Infectious Diseases, Public Health Agency of Canada, Ottawa, ON.

Joanne Hiebert (J)

National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB.

Diane MacDonald (D)

Centre for Immunization and Respiratory Infectious Diseases, Public Health Agency of Canada, Ottawa, ON.

Classifications MeSH